Well, giving Lisa (or trying to) options so late in the game is a sign of poor planning, IMO. She should have vested, exercised and cashed out by now. Now that I think about it, there were some preferred issued recently, that had dividends payed in common. Unless the price improves, the preferred holders are likely to be dismayed.
As it stands, SHMN has a large library of bioactive compounds that must be worth something, and production facilities in the tropics to produce novel things like Sangre de Drago. I doubt the real scientific types are happy with the idea that they should sell products as dietary supplements, without FDA approval, though.
This is another company that took an interesting tack to accomplish great things, but ran into the financial wall before they could deliver. I hear SHMN is not alone in this boat. CLPA made a post closing announcement, but I don't follow their research pipeline.
As far as your Private Venture, can I buy in for $100? Of course, I do understand the need for utmost secrecy giving the compressed timelines faced today. Take LTCM- they required this too, though they failed to invite me to play with them. <g> |
